GILD vs MIRM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GILD and MIRM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GILD and MIRM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Full GILD guide

Mirum Pharmaceuticals develops and sells medicines for rare liver and metabolic diseases, conditions that affect small patient populations but have almost no alternatives. Three products carry the revenue. LIVMARLI (maralixibat) is an ileal bile acid transporter inhibitor approved for Alagille syndrome and progressive familial intrahepatic cholestasis, and it did about $128.7 million in the second quarter of 2026, up roughly 46% year over year. CHOLBAM (cholic acid) treats bile-acid synthesis disorders, and CTEXLI (chenodiol), approved in early 2025, is the first and only therapy specifically cleared for cerebrotendinous xanthomatosis in adults. Those two are reported together as bile acid medicines and contributed about $47.5 million in the quarter, up roughly 20%. Total net product sales reached about $176.2 million in Q2 2026, a gain of roughly 38%, and management raised full-year 2026 guidance to $680 million to $700 million after starting the year at $630 million to $650 million.

Full MIRM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GILD drivers: Dominant HIV franchise; Oncology expansion.
• MIRM drivers: LIVMARLI compounding in two approved indications; CTEXLI as a second growth engine.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. For MIRM, the August 2026 volixibat decision is the clearest illustration of the risk: a Phase 2b study met its primary endpoint and had Breakthrough Therapy designation, and the FDA still recommended a full Phase 3, pushing an NDA to the first half of 2027 and knocking roughly 10% to 15% off the stock in a session.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GILD if you believe its drivers more; MIRM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GILD and MIRM guides.

GILD. Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

MIRM. Earnings multiples do not work on this name right now. The roughly $726 million in-process R&D charge from the Bluejay acquisition pushed trailing net loss to about $860 million, and the Q2 2026 loss was about $67.2 million, or $(1.06) a diluted share, so investors generally value Mirum on revenue and pipeline probability instead. At roughly 8 to 9 times sales the market is paying a growth-biotech multiple for a business compounding above 40%, which means a meaningful share of the price rests on programs that are not yet approved. Beta runs near 0.5, low for a biotech, because the stock moves on regulatory news rather than with the broad market.

Headline figures (approximate, early 2026): GILD shows revenue (ttm) ~$28 to 30 billion, operating margin ~thirties percent (varies with charges), net income (ttm) ~variable, affected by acquisition charges, dividend yield ~3 to 4%; MIRM shows net product sales (ttm) ~$618 million, up ~44% year over year, q2 2026 product sales ~$176.2 million, up ~38%, with LIVMARLI ~$128.7 million and bile acid medicines ~$47.5 million, 2026 guidance ~$680 million to $700 million, raised from ~$660 million to $680 million, r&d expense (q2 2026) ~$90.5 million, against SG&A of ~$81.5 million.

GILD and MIRM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GILD and MIRM exposure against your real portfolio. It is not an investment adviser.